H.C. Wainwright analyst Ed Arce maintained a Buy rating on MetaVia (MTVA – Research Report) today and set a price target of $12.00.
Ed Arce has given his Buy rating due to a combination of factors surrounding MetaVia’s promising clinical trial results for DA-1726. The drug, an oxyntomodulin analogue, has shown significant weight loss results without the need for dose titration, achieving a maximum body weight loss of up to 6.3% from baseline in a short 4-week period. Furthermore, the drug demonstrated favorable pharmacokinetics supporting once-weekly dosing, which is a convenient regimen for patients.
Additionally, DA-1726 has shown positive effects on metabolic markers, such as a reduction in fasting glucose levels, without causing hypoglycemia. The safety profile of DA-1726 is also encouraging, with only mild gastrointestinal side effects reported that resolved quickly. These promising early results suggest DA-1726 could become a leading weight loss therapy, and the upcoming 12-week data from Part 3 of the Phase 1 study is anticipated to further validate its potential.